title: The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance.
abstract: OBJECTIVE
  To investigate the correlation between serum visfatin and insulin resistance (IR) in non-diabetic essential hypertensive (EH) patients with and without IR, and to evaluate the effect of antihypertensive treatment on serum visfatin and IR in these patients.
  
  
  METHODS
  A total of 81 non-diabetic EH patients, including 54 with IR and 27 without IR, were enrolled. After two weeks wash-out, patients with IR were randomly assigned to telmisartan (group T) or amlodipine (group A) for 6 months. Blood samples were taken before and after treatment for measurement of routine biochemical parameters, visfatin and insulin resistance (measured by HOMA-IR).
  
  
  RESULTS
  Visfatin was independently correlated with HOMA-IR (r=0.845, P=0.000). After 6 months of treatment, both drugs lowered HOMA-IR, more significantly so in group T than group A (P=0.010). Serum visfatin levels increased in group T but decreased in group A.
  
  
  CONCLUSIONS
  Serum visfatin levels were higher in non-diabetic EH patients with IR compared with those without IR. Visfatin is independently correlated with HOMA-IR. Telmisartan lowers HOMA-IR to a greater extent than amlodipine. Interestingly, serum visfatin increased with telmisartan yet decreased with amlodipine treatment.
authors: Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
authors: Jianjun
authors: J
authors: Lan
authors: Xiaoni
authors: X
authors: Chen
authors: Xiaoping
authors: X
authors: Chen
authors: Si
authors: S
authors: Wang
authors: Xin
authors: X
authors: Zhang
authors: Kai
authors: K
authors: Wu
authors: Sen
authors: S
authors: He
authors: Yong
authors: Y
authors: Peng
authors: Lingyun
authors: L
authors: Jiang
authors: Longxin
authors: L
authors: Li
authors: Liyan
authors: L
authors: Wan
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy*; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D011446:Prospective Studies
chemical_list: D000959:Antihypertensive Agents; D054409:Nicotinamide Phosphoribosyltransferase